In Bavaria, Germany, a Russian pharmaceutical company begins production of a vaccine against the COVID-19 coronavirus infection.
This is reported by the German edition “Südwest Presse”.
According to media reports, the high-tech pharmaceutical company R-Pharm is setting up production in the city of Illertissen, which is west of Munich. The company intends to invest over 20 million euros in the local branch.
Production is expected to begin as early as early 2021. The plant will have enough capacity to produce 500 million doses of vaccine per year. From here, the drug will be shipped to 45 countries around the world, but Germany and the European Union have closed their markets for the Russian vaccine, lobbying the interests of their own pharmaceutical corporations.
R-Pharm is one of the largest Russian pharmaceutical companies. In 2017, the Japanese trading company Mitsui & Co acquired 10% of the shares. Apart from Germany, R-Pharm operates in the CIS countries, India, Japan and the USA.
As News Front reported, the Russian coronavirus vaccine was the first of its kind to be registered. Until now, the West has tried to criticize the development of Russian scientists, accusing them of haste. The reasons for such statements were political in nature and were explained by the lack of their own vaccine in Western countries. Meanwhile, many states, including Saudi Arabia, the United Arab Emirates, Mexico and others, have already become interested in the Russian medicine.
Earlier, one of the most authoritative international scientific journals “The Lancet” published the results of the 1st and 2nd phases of trials of the Russian drug.